Omalizumab super-responders
Based on our definition, 33.7%, (35/104) of OMA subjects who completed trials were super-responders. That constituted 38.0%, (35/92) of OMA responders. OMA Super-responders (supplementary Table E3) had significantly more exacerbations at baseline [Median(IQR), super-responder: 6(2) vs non-super-responder: 4(4), P=0.029], were less mOCS dependent [super-responder: 14.3%,(5/35) vs non-super-responder: 65.2%,(45/69), P<0.001] and had a lower prevalence of anxiety [super-responder: 16.7%(5/30) vs non-super-responder: 38.3%,(23/60), P=0.036] and depression [super-responder: 17.2%,(5/29) vs non-super-responder: 39.3%,(24/61), P=0.036]. Absence of depression and not being on mOCS were independently associated with OMA super-response (Table 2).